President Donald Trump is reportedly preparing to dismiss FDA Commissioner Marty Makary, according to sources cited by The Wall Street Journal and summarized by FiercePharma. Makary, confirmed in March 2025, has endured a bruising 14‑month tenure marked by deep staff cuts and rapid turnover across the agency. His resistance to approving fruit‑flavored vaping products reportedly infuriated the president just as the FDA authorized 45 types of e‑cigarettes earlier this week. Within the same period, former FDA oncology chief Richard Pazdur resigned after only a month leading the Center for Drug Evaluation and Research, citing political interference, while Vinay Prasad left the Center for Biologics Evaluation and Research amid tensions surrounding cell and gene therapy oversight. The White House has not yet confirmed a final decision.
If Trump proceeds, Makary’s removal would lengthen a period of regulatory volatility that has already unsettled the biopharma sector. The loss of senior directors, Pazdur and Prasad among them, has left sponsors questioning continuity in oncology and gene therapy supervision. Review cycles may slow, launch timelines could stretch, and confidence in regulatory consistency has thinned. For payers and PBMs, that means fewer new entrants to keep prices in check. Manufacturers, meanwhile, face a confusing trade‑off: near‑term enforcement slack paired with long‑term uncertainty about what rules even hold.
A new commissioner aligned with the administration’s deregulatory leanings is expected to speed approvals in politically favored areas such as vaping or fertility therapeutics. Yet the drain of experienced career staff, described by insiders as the departure of the agency’s “memory,” points to a deeper loss of institutional knowledge. Whether this period represents a passing disruption or the start of a fully politicized FDA, nobody really knows yet. Still, amid the noise, the biopharma industry keeps shipping trial data, lobbying budgets keep climbing, and investors keep guessing. That’s Washington. For deeper analysis on regulatory risk and commercialization timelines, see RxNews.ai.
